XIFAXAN® 550 mg
PRESCRIPTION MEDICINE
XIFAXAN® 550 mg is Rifaximin. XIFAXAN® 550 mg is indicated for “Prevention of the recurrence of hepatic encephalopathy where other treatments have failed or are contraindicated”.
XIFAXAN® 200 mg
PRESCRIPTION MEDICINE
XIFAXAN® 200 mg (Rifaximin) is indicated for the treatment of patients (≥ 12 years of age) with travellers’ diarrhoea caused by non-invasive strains of Escherichia coli.
Product under licence from Alfasigma S.p.A. XIFAXAN is a registered trademark of the Alfasigma group of companies, licensed to the Norgine group of companies.
ANZ/COR/0814/0002a(1). Date of Preparation: September 2018
